Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
129.08
+2.08 (+1.64%)
Streaming Delayed Price
Updated: 11:08 AM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,016,172
Open
129.69
Bid (Size)
129.05 (2)
Ask (Size)
129.11 (1)
Prev. Close
127.00
Today's Range
128.76 - 132.80
52wk Range
99.14 - 133.10
Shares Outstanding
2,531,374,696
Dividend Yield
2.26%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q1 2024
Today 10:54 EDT
MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Meta Falls 15% On Great Earnings, Tesla Rises 12% On Ugly Earnings – Here Is The Real Reason
Today 10:51 EDT
To gain an edge, this is what you need to know today.
Via
Benzinga
Performance
YTD
+13.99%
+13.99%
1 Month
+3.01%
+3.01%
3 Month
+8.58%
+8.58%
6 Month
+24.56%
+24.56%
1 Year
+10.77%
+10.77%
More News
Read More
Merck Rides Keytruda To Another Beat-And-Raise, But Diabetes Headwinds Persist
Today 6:30 EDT
Via
Investor's Business Daily
Merck Announces First-Quarter 2024 Financial Results
Today 6:30 EDT
From
Merck & Co., Inc.
Via
Business Wire
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
April 24, 2024
Via
Benzinga
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
April 23, 2024
Via
Benzinga
Looking Into Merck & Co's Recent Short Interest
April 23, 2024
Via
Benzinga
3 Under-The-Radar Stocks With Positive Potential
April 21, 2024
Via
Talk Markets
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Today 6:17 EDT
Via
Benzinga
Investor Alert: Prepare for the Market Crash With These 3 Stocks
April 23, 2024
Via
InvestorPlace
Unveiling 17 Analyst Insights On Merck & Co
April 18, 2024
Via
Benzinga
Market Whales and Their Recent Bets on MRK Options
April 17, 2024
Via
Benzinga
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
April 11, 2024
Via
Chartmill
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
April 23, 2024
Via
InvestorPlace
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
April 17, 2024
Via
InvestorPlace
Exposures
Product Safety
3 Dow Stocks to Buy Now: Q2 Edition
April 16, 2024
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
April 16, 2024
Via
Talk Markets
Better Growth Play: Merck or The Vanguard Growth Index Fund?
April 15, 2024
Via
The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Via
Benzinga
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
April 14, 2024
Via
The Motley Fool
1 New Green Flag for Moderna and Merck Stock
April 12, 2024
Via
The Motley Fool
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
April 12, 2024
Via
InvestorPlace
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
April 11, 2024
Via
Benzinga
Exposures
COVID-19
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
April 11, 2024
Via
InvestorPlace
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
April 10, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.